Werewolf TherapeuticsHOWL
NASDAQPharmaceuticals
No cached AI snapshot yet for HOWL.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
39 employees48.60M shares outstandinglisted 2021-04-30
Next earnings ~May 5, 2026
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Latest News
Showing market-wide stock news
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Warsh’s Fed expected to hike rates 25bp as dot plot takes center stage
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Equities: Fed focus and energy shock – Deutsche Bank
Related Stocksin Pharmaceuticals
Ready to see the live AI view on HOWL?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing HOWL side-by-side with live signals.